Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.therap.2021.05.003 http://scihub22266oqcxt.onion/10.1016/j.therap.2021.05.003 34059351!8103768!34059351     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Therapie 2021 ; 76 (4): 297-303 Nephropedia Template TP {{tp|p=34059351|t=2021. French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge |pdf=|usr=}}{{34059351}} gab.com Text French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge JO: Therapie http://www.kidney.de/pget.php?&tw=1&pmid=34059351 #FOAvip In this special issue, we present the main highlights of the first weeks of pharmacovigilance monitoring of coronavirus disease 2019 (COVID-19) vaccines in this unprecedented situation in France: the deployment of a vaccination during an epidemic period with the aim of vaccinating the entire population and the intense pharmacovigilance and surveillance of these vaccines still under conditional marketing authorizations. In this unprecedented situation, the cross approach and interaction between the French pharmacovigilance network and French National Agency for the Safety of Medicines and Health Products (ANSM) has been optimized to provide a real-time safety related to COVID-19 vaccines. Every week, pair of regional pharmacovigilance centers gathered safety data from the French pharmacovigilance network, to acutely expertise all the adverse drug reactions (ADRs) reported with each COVID-19 vaccine within a direct circuit with ANSM. Results of this expertise are presented and discussed with ANSM in order to raise safety signals and take appropriate measures if necessary. These reports are then published online. At the 25th of March 2021, more than 9 815 000 doses were injected and 20,265 ADRs were reported, mostly non-serious (76%). Several potential or confirmed signals were raised at the european level for those vaccines and others ADRs are under special attentions. This underlines the adaptiveness of the French pharmacovigilance system to both the identification of new patient profiles experiencing ADRs and the evolution of the vaccine strategy. Such an efficiency is necessary to manage a careful and acute surveillance of these new COVID-19 vaccines for and to face the pandemic at the same time. Twit Text FOAVip French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge ????Therapie http://www.kidney.de/pget.php?&tw=1&pmid=34059351 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34059351 #FOAvip English Wikipedia <ref>{{Cite pmid|34059351}}</ref> French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge #MMPMID34059351 Lacroix C; Salvo F; Gras-Champel V; Gautier S; Massy N; Valnet-Rabier MB; Grandvuillemin A; Mounier C; Benkebil M; Pariente A; Jonville-Bera AP; Micallef J Therapie 2021[Jul]; 76 (4): 297-303 PMID34059351show ga In this special issue, we present the main highlights of the first weeks of pharmacovigilance monitoring of coronavirus disease 2019 (COVID-19) vaccines in this unprecedented situation in France: the deployment of a vaccination during an epidemic period with the aim of vaccinating the entire population and the intense pharmacovigilance and surveillance of these vaccines still under conditional marketing authorizations. In this unprecedented situation, the cross approach and interaction between the French pharmacovigilance network and French National Agency for the Safety of Medicines and Health Products (ANSM) has been optimized to provide a real-time safety related to COVID-19 vaccines. Every week, pair of regional pharmacovigilance centers gathered safety data from the French pharmacovigilance network, to acutely expertise all the adverse drug reactions (ADRs) reported with each COVID-19 vaccine within a direct circuit with ANSM. Results of this expertise are presented and discussed with ANSM in order to raise safety signals and take appropriate measures if necessary. These reports are then published online. At the 25th of March 2021, more than 9 815 000 doses were injected and 20,265 ADRs were reported, mostly non-serious (76%). Several potential or confirmed signals were raised at the european level for those vaccines and others ADRs are under special attentions. This underlines the adaptiveness of the French pharmacovigilance system to both the identification of new patient profiles experiencing ADRs and the evolution of the vaccine strategy. Such an efficiency is necessary to manage a careful and acute surveillance of these new COVID-19 vaccines for and to face the pandemic at the same time. |*Adverse Drug Reaction Reporting Systems[MESH] |*COVID-19/epidemiology/immunology/prevention & control[MESH] |*Pharmacovigilance[MESH] |COVID-19 Vaccines/*adverse effects[MESH] |Female[MESH] |France/epidemiology[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH]French organization for the pharmacovigilance of COVID-19 vaccines: A (epmc).pdf DeepDyve Pubget Overpricing